NCT00562614

Safety and Effect of Oral Doses of 5mg or 10mg of SLx-2101 for 14 Days in Patients With Hypertension

A Pilot Phase IIa Randomised, Double-blind, Placebo-controlled, Crossover Study to Examine the Safety, Tolerability and Pharmacodynamic Effects on Blood Pressure of Repeat Oral Doses of SLx-2101 5 mg or 10 mg Once Daily for up to 14 Days in Patients With Hypertension

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 38 (actual)
• Sponsor: Response Pharmaceuticals · Industry
• Sex: All
• Age: 18 Years – 70 Years
• Healthy volunteers: Not accepted

Summary

The purpose is to determine the effect of SLx-2101 dosed at 5mg or 10mg for 14 days on systolic, diastolic pressures and heart rate in patients with hypertension.

Detailed description

1. Placebo-corrected supine peripheral systolic, diastolic blood pressures and heart rate 2. 24 hour ambulatory blood pressure and heart rate 3. Safety and tolerability

Conditions

• Hypertension

Interventions

Type	Name	Description
DRUG	SLx-2101

Timeline

• Start date: 2007-06-01
• Primary completion: 2007-12-01
• Completion: 2007-12-01
• First posted: 2007-11-22
• Last updated: 2023-11-18

Locations

1 site across 1 country: Germany